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Abstract
Rotavirus vaccines are highly effective at preventing gastroenteritis in young children and are now universally
recommended for infants in the US. We studied patterns of use of rotavirus vaccines among US infants with commercial
insurance. We identified a large cohort of infants in the MarketScan Research Databases, 2006–2010. The analysis was
restricted to infants residing in states without state-funded rotavirus vaccination programs. We computed summary
statistics and used multivariable regression to assess the association between patient-, provider-, and ecologic-level
variables of rotavirus vaccine receipt and series completion. Approximately 69% of 594,117 eligible infants received at least
one dose of rotavirus vaccine from 2006–2010. Most infants received the rotavirus vaccines at the recommended ages, but
more infants completed the series for monovalent rotavirus vaccine than pentavalent rotavirus vaccine or a mix of the
vaccines (87% versus 79% versus 73%, P,0.001). In multivariable analyses, the strongest predictors of rotavirus vaccine
series initiation and completion were receipt of the diphtheria, tetanus and acellular pertussis vaccine (Initiation: RR = 7.91,
95% CI = 7.69–8.13; Completion: RR = 1.26, 95% CI = 1.23–1.29), visiting a pediatrician versus family physician (Initiation:
RR = 1.51, 95% CI = 1.49–1.52; Completion: RR = 1.13, 95% CI = 1.11–1.14), and living in a large metropolitan versus smaller
metropolitan, urban, or rural area. We observed rapid diffusion of the rotavirus vaccine in routine practice; however,
approximately one-fifth of infants did not receive at least one dose of vaccine as recently as 2010. Interventions to increase
rotavirus vaccine coverage should consider targeting family physicians and encouraging completion of the vaccine series.
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Introduction
Rotavirus gastroenteritis is a leading cause of hospitalizations
and emergency department visits among young children in the US
[1]. The recently licensed rotavirus vaccines, RotaTeqH (Rotavirus
Vaccine, live, oral, pentavalent) [RV5] (Merck & Co., Inc.) and
RotarixH (Rotavirus Vaccine, live, oral, monovalent) [RV1]
(GlaxoSmithKline Biologicals), have dramatically reduced inci-
dence of healthcare utilization for rotavirus infection [2]. These
vaccines have been recommended for routine use among US
infants by the Advisory Committee on Immunization Practices
(ACIP) since 2006 [3,4].
Despite these recommendations, the Centers for Disease
Control and Prevention (CDC) estimated that only 67% of eligible
children 19–35 months in the US had completed a rotavirus
vaccine series in 2011 [5]. Among nine recommended pediatric
vaccines assessed by the National Immunization Survey (NIS) in
2011, only the hepatitis A vaccine had lower coverage than the
rotavirus vaccine in the US [5,6]. Little is known about why it can
take several years or more for newly recommended vaccines like
the rotavirus vaccine to reach high coverage levels, but studies to-
date suggest that type of physician visited, geographic residence,
socio-economic status, and race may be important predictors [5–
8]. Considering that the US Department of Health and Human
Services (HHS) Healthy People 2020 objectives include vaccinat-
ing at least 80% of children with two or more doses of rotavirus
vaccine by 2020 and no catch-up schedule for rotavirus vaccines
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exist, further exploration regarding the determinants of rotavirus
vaccine uptake is warranted [9].
Using data from a large population of infants with commercial
insurance, we study patterns of use of rotavirus vaccine. We
examine individual, provider, and ecologic correlates of rotavirus
vaccine use and vaccine series completion. We hypothesize that
receipt of other childhood vaccines (e.g., diphtheria, tetanus, and
acellular pertussis (DTaP) vaccines) and the type of physician
visited will be the most important predictors of rotavirus vaccine
series initiation and completion. Our study also examines
timeliness of rotavirus vaccine administration as per the 2009
ACIP recommendations and patterns of vaccine uptake from 2006
through 2010 [4].
Materials and Methods
Infants born in a hospital or outpatient setting between January
1, 2006 and September 30, 2010 were identified from the
MarketScan Research Databases (Copyright  Thomson Truven
Healthcare, Inc). The MarketScan Research Databases are
available for purchase and contain commercial insurance claims
data from .111 million individuals in all 50 US states. In 2010,
the database included approximately 920,000 infants, correspond-
ing to 25% of the US birth cohort and 50% of the US birth cohort
with commercial insurance [10,11]. Since the data source does not
provide birth dates, we used the International Classification of
Clinical Diseases, Ninth Revision, Clinical Modification (ICD-9-
CM) codes for live born infants, V30–V39, to define the birth date
of infants [12]. If an infant had V30–V39 codes on multiple dates,
the date of the first code was used as the birth date, and those
without such codes and corresponding dates were excluded.
Infants with birth dates occurring after administration of rotavirus
vaccines, likely due to coding errors, were excluded.
For infants born between January 2006 and February 2010,
additional eligibility criteria included having at least eleven months
of continuous enrollment in a payer plan captured by our data
source. For infants born between March and September 2010,
continuous enrollment was defined as enrollment at every month
from birth until the end of the 2010 calendar year (the end of
available data). In order to ensure adequate follow-up time, only
infants born before March 2010 were included in assessments of
vaccine series completion.
RV5 and RV1 vaccination status was assessed using the Current
Procedural Terminology (CPT) codes, 90680 and 90681. We
required infants to have at least one outpatient claim because we
thought it was important for our cohort to include only infants that
utilized the healthcare system through their private insurance plan
to reduce potential misclassification of rotavirus vaccination status.
To further reduce exposure misclassification, we excluded infants
residing in 13 states with state-funded vaccine programs (Alaska,
Idaho, Massachusetts, Maine, North Dakota, New Hampshire,
New Mexico, Oregon, Rhode Island, Vermont, Washington,
Wisconsin, and Wyoming) except for the cohort of infants used to
examine adherence to the recommended vaccine schedule [2].
We used the 2009 ACIP recommendations to assess adherence
to the recommended rotavirus vaccine schedule for all calendar
years, 2006–2010. If the first dose of rotavirus vaccine was given
before the age of six weeks, zero days or after the age of fourteen
weeks, six days, then the recommendations were not met. We also
considered recommendations to have been violated if any dose was
given after the age of eight months, zero days, or if the minimum
interval between two doses was less than four weeks.
We calculated simple frequencies, and performed bivariate and
multivariable regression analyses using log-risk models that were
limited to individual, provider, and ecological characteristics
thought to be associated with receipt of at least one dose of
rotavirus vaccine, and identifiable in the available data. We also
used the same potential individual, provider, and ecological
characteristics to explore predictors of rotavirus vaccine series
completion. In order to examine whether predictors of rotavirus
vaccination changed over time, we repeated the above analyses,
restricting the cohort to infants born in 2006 and then 2009.
Infants with missing data on any potential predictors were
excluded from both of these analyses.
We identified all potential predictors of rotavirus vaccination a
priori. Individual level variables included sex, DTaP vaccination
status ($1 dose versus 0 doses), number of siblings ,10 years old,
mother’s age at birth, and overnight hospitalizations prior to the
first dose of rotavirus vaccine or by the maximum age at which the
first dose of rotavirus vaccine could have been administered as per
the ACIP guidelines (14 weeks, 6 days). Variables for race and
socioeconomic status were not available. Provider and health plan
characteristics included the type of physician visited during $70%
of the infant’s outpatient visits (pediatrician, family physician,
other providers, or no consistent provider type); the network of the
care received during $70% of the infant’s outpatient visits (in-
network, or out-of-network or mixed); and the infant’s type of
health plan (basic, comprehensive, high-deductible; Exclusive
Provider Organization (EPO) or Preferred Provider Organization
(PPO); Health Maintenance Organization (HMO); Point of
Service (POS) or POS with capitation; or Consumer Directed
Health Plan (CDHP)). All provider and health plan variables were
assessed prior to rotavirus vaccination, or fifteen weeks of age if the
infant was unvaccinated. Our ecologic factors of interest were
region of the infant’s residence (Northeast, Midwest, South, or
West) and rurality. In order to better measure rurality, we linked
the US Department of Agriculture (USDA), Economic Research
Service 2003 rural-urban continuum codes to the claims database
via five-digit Federal Information Processing Standard (FIPS)
codes. The 2003 rural-urban continuum codes distinguish
metropolitan counties by the population size of the metropolitan
area, and nonmetropolitan counties by the population size, degree
of urbanization, and adjacency to metropolitan areas. These codes
classify every US County into either one of three metropolitan
categories, or one of six nonmetropolitan categories.
Ethics statement
This study was considered exempt from human subjects review




Approximately half (51%) of 2.80 million infants identified in
the enrollment files between January 2006 and December 2010
had an ICD-9-CM birthing code and corresponding date of
service (Figure S1). Infants that were excluded due to missing data
generally lacked information on their mother’s age at birth. After
additional exclusions, our final cohorts to assess predictors of
rotavirus vaccine initiation and completion included 594,117 and
324,264 infants, respectively.
Temporal trends of rotavirus vaccine uptake
Rotavirus vaccine uptake ($1 dose) among infants in our cohort
increased from 0% when RV5 was licensed (February 2006) to
25% when the first ACIP recommendations were published
(August 2006) (Figure 1). Rotavirus vaccine uptake then increased
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even more rapidly, doubling to 49% by December 2006. The
percentage of infants receiving at least one dose of rotavirus
vaccine continued to grow steadily, reaching 62% by April 2007
and reaching 70% beginning November 2007. Throughout 2009
and 2010, a median of 81% (range, 78%–83%) of eligible infants
were vaccinated with at least one dose of rotavirus vaccine each
month. Among the infants receiving a rotavirus vaccine during our
study period, 92% received RV5, 5% received RV1, and 3%
received a combination of the two vaccines.
Adherence to the 2009 ACIP recommendations
The median and inter-quartile range of ages at which infants
received doses of rotavirus vaccine followed the 2009 ACIP
guidelines of two, four, and six months of age (Table 1). Almost all
infants received their rotavirus vaccines between the minimum
(6 weeks) and maximum (8 months, 0 days) recommended ages,
and received dose one and dose two at least four weeks apart.
Although the 2009 ACIP guidelines do not specify a maximum
interval in which two doses should be given, 18% of infants
received a second dose of rotavirus vaccine more than 10 weeks
after their first dose, and 7% of infants received their second dose
more than 12 weeks after their first dose. Across all years,
approximately 8% of infants received their first dose of rotavirus
vaccine at ages older than the maximum recommended age for the
first dose (14 weeks, 6 days), with 19% of infants in 2006 and 6.0–
8.5% of infants from 2007 to 2010, receiving their first dose after
age 14 weeks, 6 days. Although most infants who initiated
rotavirus vaccination completed the full series, more infants
completed the series for RV1 than RV5 or a combination of the
two vaccines (87% versus 79% versus 73%, P,0.001).
Univariate, bivariate and multivariable analyses
Among 594,117 infants, 69% received at least one dose of
rotavirus vaccine between February 2006 and December 2010
(Table 2). Most infants in the cohort were also vaccinated with at
least one dose of DTaP, were born to mothers 25–39 years of age,
were first born children or had one older sibling, visited in-network
physicians, were enrolled in EPO or PPO health plans, received
outpatient care from pediatricians, resided in the Midwest or
South, and lived in large metropolitan areas.
The strongest predictors of rotavirus vaccine initiation ($1 dose)
among infants born January 2006-September 2010 were receipt of
$1 dose of DTaP (multivariable: RR = 7.50, 95% CI = 7.30–
7.71), and visiting a pediatrician versus family physician for
routine care (multivariable: RR = 1.51, 95% CI = 1.49–1.52). In
multivariable analyses, infants were slightly less likely to receive a
rotavirus vaccine if they lived in the Northeast as opposed to the
South, or in a small urban or rural area as opposed to a large
metropolitan area. As the number of siblings less than 10 years of
age in the household increased, infants became less likely to
receive a rotavirus vaccine.
In order to determine whether predictors of rotavirus vaccine
initiation changed over time, we also examined predictors of
infants born when RV5 was first licensed (2006) with those born
three years after RV5 licensure (2009). In multivariable analyses,
compared to the 2006 birth cohort, visiting a pediatrician versus a
family physician in the 2009 birth cohort was a less important
predictor of rotavirus vaccine initiation (2006: RR = 2.15, 95%
CI = 2.02–2.28; 2009: RR = 1.35, 95% CI = 1.32–1.37) as was
residing in a metropolitan area with less than one million
population versus an area with at least one million population.
Family physicians often provide care more frequently in rural
areas, and infants visiting family physicians or residing in rural
areas were independently less likely to receive a dose of rotavirus
vaccine. We therefore explored potential interactions between the
type of physician visited (pediatrician versus family physician) for
routine care and population size of residence (metropolitan areas
versus non-metropolitan areas), but did not find an interaction in
these post-hoc analyses (Figure 2).
The most important predictors of rotavirus vaccine series
completion were receipt of DTaP and receiving routine care from
a pediatrician as opposed to a family physician. The strength of the
associations in multivariable analyses were 6-fold and 1.3-fold
smaller than in the multivariable analyses of rotavirus vaccine
initiation, and the strength of the association decreased from 2006
to 2009 (Table 3). Infants born to younger mothers (,25 years)
and with more siblings were slightly less likely to complete the
rotavirus vaccine series, and this trend remained consistent in 2006
and 2009. Infants residing outside of metropolitan areas were
generally less likely to complete the rotavirus vaccine series.
Figure 1. Number and percent of infants vaccinated with $1 dose of rotavirus vaccine, February 2006-November 2010
(n = 825,300).
doi:10.1371/journal.pone.0073825.g001
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Region of residence was not an important predictor of vaccine
series completion.
Discussion
We observed rapid diffusion of the rotavirus vaccine into
routine practice shortly after licensure in the US. Approximately
three quarters of infants born from early 2008 through mid-2010,
received two or more doses. This estimate is slightly higher than
the CDC estimate that analyzed data for infants born during
approximately the same time period using a population-based
telephone survey (NIS), and 5% lower than the HHS’ Healthy
People 2020 goal [5,9]. Our estimate may be higher than the
CDC estimate and may have overestimated the progress towards
the Healthy People 2020 goal for several reasons. First, our
population included only infants with commercial insurance who
may be more likely to be vaccinated than other infant populations,
such as the uninsured or those with Medicaid insurance. Second,
our cohort consisted of a non-population based sample of infants.
Since the MarketScan Research Databases have increased in size
over time, our data were weighted towards the later years (e.g.,
2010) when rotavirus vaccine coverage was relatively high
compared to the earlier years. In addition, infants residing in
rural and small urban areas were less likely to be vaccinated in our
study, but also underrepresented.
It was surprising that one-quarter of eligible infants received at
least one dose of rotavirus vaccine prior to the publication of the
first ACIP recommendations in August 2006. This reflects the
importance of other communication networks and the apparent
readiness of the manufacturer, insurance companies, and provid-
ers to deliver the rotavirus vaccine. Despite the initial rapid uptake
of the rotavirus vaccine, approximately one-fifth of infants were
Table 1. Adherence to the rotavirus vaccination 2009 ACIP guidelines (n = 486,295)1.
Variable Number (%)
Median age in days (IQR)
Dose 1 63 (61–69)
Dose 2 126 (123–135)
Dose 3 (RV5 only) 188 (184–197)
RV5, number of doses received in series
One (incomplete) 30,256 (6.8)
Two (incomplete) 63,294 (14.2)
Three (complete) 349,599 (78.4)
Four or more (too many doses) 2589 (0.6)
RV1, number of doses received in series
One (incomplete) 3509 (13.5)
Two (complete) 21,588 (83.3)




Complete (too many doses) 885 (6.1)




Administered first dose too late
(.14 weeks, 6 days)
No 447,442 (92.0)
Yes 39,557 (8.0)
Administered any dose too late
(.8 months, 0 days)
No 476,647 (98.0)
Yes 9648 (2.0)
Minimum interval between first two doses violated (,4 weeks)
No 450,922 (99.6)
Yes 1608 (0.4)
1Infants vaccinated with RV5, RV1, or a mixed series and enrolled $11 months Abbreviations: ACIP, Advisory Committee on Immunization Practices; IQR, interquartile
range; RV1, monovalent rotavirus vaccine; RV5, pentavalent rotavirus vaccine.
2A complete mixed series was defined as receiving 3 rotavirus vaccine doses ($1 dose of RV1 and $1 dose of RV5) when dose 1 and dose 2 were not both RV1.
doi:10.1371/journal.pone.0073825.t001
Rotavirus Vaccine Uptake in US Infants, 2006–2010
PLOS ONE | www.plosone.org 4 September 2013 | Volume 8 | Issue 9 | e73825



















Overall 409,557 (68.9) – – – –
Sex
Female 200,442 (69.0) Ref Ref. Ref. Ref.
Male 209,115 (68.9) 1.00 (1.00–1.00) 1.00 (1.00–1.00) 1.00 (0.98–1.02) 1.00 (1.00–1.00)
DTaP vaccination ($1 dose)
No 4645 (9.4) Ref Ref. Ref. Ref.
Yes 404,912 (74.3) 7.91 (7.69–8.13) 7.50 (7.30–7.71) 7.28 (6.59–8.04) 6.95 (6.57–7.34)
Overnight hospitalization
No 397,832 (69.1) Ref Ref. Ref. Ref.
Yes 11,725 (64.3) 0.93 (0.92–0.94) 0.96 (0.95–0.97) 1.05 (1.00–1.10) 0.99 (0.98–1.00)
Number of siblings ,10 years
0 187,647 (71.2) Ref Ref. Ref. Ref.
1 156,922 (68.7) 0.96 (0.96–0.97) 0.97 (0.97–0.97) 0.96 (0.94–0.98) 0.99 (0.98–0.99)
2 52,803 (64.9) 0.91 (0.91–0.92) 0.94 (0.94–0.94) 0.95 (0.92–0.97) 0.97 (0.96–0.97)
3 or more 12,185 (58.3) 0.81 (0.81–0.83) 0.89 (0.88–0.90) 0.91 (0.86–0.96) 0.90 (0.88–0.91)
Mother’s age (years)
,25 36,376 (63.7) 0.91 (0.90–0.91) 0.95 (0.95–0.96) 0.96 (0.93–0.99) 0.99 (0.98–1.00)
25-,30 130,089 (68.9) 0.98 (0.97–0.98) 0.99 (0.99–0.99) 0.98 (0.96–1.00) 1.00 (1.00–1.00)
30-,35 152,610 (70.4) Ref Ref. Ref. Ref.
35-40 75,185 (69.2) 0.98 (0.98–0.99) 0.99 (0.98–0.99) 1.02 (0.99–1.05) 0.99 (0.99–1.00)
$40 15,297 (67.5) 0.96 (0.95–0.97) 0.97 (0.97–0.98) 0.95 (0.90–1.00) 0.98 (0.97–0.99)
Primary provider type
Pediatrician 266,740 (75.8) 1.64 (1.63–1.66) 1.51 (1.49–1.52) 2.15 (2.02–2.28) 1.35 (1.32–1.37)
Family physician 15,790 (46.1) Ref. Ref. Ref. Ref.
Other providers 75,312 (61.3) 1.33 (1.31–1.34) 1.31 (1.29–1.32) 1.77 (1.66–1.88) 1.27 (1.25–1.30)
No consistent provider type 51,715 (60.6) 1.31 (1.30–1.33) 1.30 (1.28–1.32) 1.53 (1.43–1.64) 1.23 (1.21–1.26)
Network of provider type
In-network 368,525 (69.4) 1.07 (1.07–1.08) 1.00 (1.00–1.00) 0.91 (0.88–0.94) 0.99 (0.98–1.00)





7597 (68.0) 0.99 (0.98–1.01) 1.02 (1.01–1.03) 0.76 (0.70–0.83) 1.01 (0.99–1.03)
EPO or PPO 293,141 (68.6) Ref. Ref. Ref. Ref.
HMO 59,901 (70.5) 1.03 (1.02–1.03) 0.99 (0.98–0.99) 0.90 (0.88–0.93) 1.00 (0.99–1.01)
POS or POS with capitation 36,495 (68.5) 1.00 (0.99–1.01) 0.97 (0.96–0.97) 0.98 (0.95–1.01) 1.00 (0.99–1.01)
CDHP 12,423 (72.9) 1.06 (1.05–1.07) 1.03 (1.02–1.04) 0.95 (0.90–1.01) 1.01 (0.99–1.01)
Region of residence
Northeast 48,468 (68.2) 0.96 (0.95–0.96) 0.92 (0.92–0.93) 0.73 (0.70–0.76) 0.89 (0.89–0.90)
Midwest 122,396 (66.0) 0.93 (0.92–0.93) 0.98 (0.98–0.98) 0.94 (0.92–0.96) 1.01 (1.01–1.02)
South 202,587 (71.3) Ref. Ref. Ref. Ref.
West 36,106 (67.9) 0.95 (0.95–0.96) 0.97 (0.97–0.98) 0.72 (0.69–0.76) 0.97 (0.96–0.98)
Type of residence
Metro with $1 M pop 250,066 (71.2) Ref. Ref. Ref. Ref.
Metro with 250,000 – 1 M pop 74,009 (70.3) 0.99 (0.98–0.99) 1.04 (1.03–1.04) 1.16 (1.13–1.19) 1.02 (1.01–1.02)
Metro with ,250,000 pop 39,238 (67.8) 0.95 (0.95–0.96) 1.01 (1.00–1.02) 1.20 (1.16–1.23) 1.00 (0.99–1.01)
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still not receiving the vaccine in January 2009 and coverage has
failed to further increase since this time. Education interventions,
particularly those targeted at family physicians should be
considered. This recommendation is consistent with the results
of a 2007 nationally-representative survey of pediatricians and
family physicians which found that pediatricians were much more
likely to administer the rotavirus vaccine to eligible infants than
family physicians, possibly because family physicians were more
concerned with vaccine safety and adding additional vaccines to
the childhood schedule than pediatricians [8]. Studies examining
other vaccines in various populations of infants and young children
have also shown that family physicians may be less likely to adopt
and may be less knowledgeable about vaccine recommendations
than pediatricians [13].
Since most children who received a rotavirus vaccine also
received at least one other recommended childhood vaccine (e.g.,
DTaP), it appears that neither parents nor providers are ‘‘cherry-
picking’’ vaccines. Rather, it appears that infants either generally
receive the recommended childhood vaccines or do not. This
observation is further supported by a post-hoc analysis that found
a high correlation between the number of doses of DTaP (one,




















Urban with $20,000 pop,
adjacent to metro area
13,445 (61.9) 0.87 (0.86–0.88) 0.98(0.97–0.99)( 1.02 (0.97–1.07) 0.98 (0.96–0.99)
Urban with $20,000 pop, 6348 (56.8) 0.80 (0.78–0.81) 0.93 (0.92–0.94) 0.99 (0.92–1.06) 0.96 (0.94–0.98)
not adjacent to metro area
Urban with 2500–19,999 pop,
adjacent to metro area
15,416 (58.5) 0.82 (0.81–0.83) 0.96 (0.95–0.97) 0.95 (0.91–1.00) 0.96 (0.94–0.97)
Urban with 2500–19,999 pop,
not adjacent to metro area
7048 (50.5) 0.71 (0.70–0.72) 0.90 (0.89–0.92) 0.91 (0.84–0.97) 0.94 (0.92–0.96)
Rural or ,2500 population,
adjacent to metro area
2146 (63.7) 0.89 (0.87–0.92) 0.99 (0.97–1.01) 1.01 (0.90–1.15) 0.99 (0.96–1.02)
Rural or ,2500 population, 1841 (56.1) 0.79 (0.76–0.81) 0.98 (0.95–1.00) 1.04 (0.90–1.20) 0.94 (0.90–0.98)
not adjacent to metro area
Abbreviations: CDHP, Consumer Directed Health Plan; DTaP, diphtheria, tetanus, and acellular pertussis; EPO, Exclusive Provider Organization; HMO, Health Maintenance
Organization; Metro, metropolitan; Pop, population; POS, Point of Service; PPO, Preferred Provider Organization; RV1, monovalent rotavirus vaccine; RV5, pentavalent
rotavirus vaccine.
doi:10.1371/journal.pone.0073825.t002
Figure 2. Number and percent of infants vaccinated with $1 dose of rotavirus vaccine by physician type and geography1
(n = 385,291). 1Non-metropolitan geographic areas included any urban or rural designation as defined by the US Department of Agriculture 2003
rural-urban continuum codes, while metropolitan areas included any of the three metropolitan designations.
doi:10.1371/journal.pone.0073825.g002
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Overall 259,701 (80.1) – – – –
Sex
Female 127,460 (80.3) Ref. Ref. Ref. Ref.
Male 132,241 (79.9) 1.00 (0.99–1.00) 1.00 (0.99–1.00) 0.98 (0.97–1.00) 1.00 (0.99–1.00)
DTaP vaccination ($1 dose)
No 2502 (62.6) Ref. Ref. Ref. Ref.
Yes 257,199 (80.3) 1.28 (1.25–1.31) 1.26 (1.23–1.29) 1.47 (1.32–1.63) 1.24 (1.19–1.29)
Overnight hospitalization
No 252,144 (80.2) Ref. Ref. Ref. Ref.
Yes 7557 (77.3) 0.96 (0.95–0.98) 0.97 (0.96–0.99) 1.00 (0.96–1.04) 0.97 (0.95–0.98)
Number of siblings ,10 years
0 120,863 (82.2) Ref. Ref. Ref. Ref.
1 99,233 (79.5) 0.97 (0.96–0.97) 0.96 (0.96–0.97) 0.96 (0.95–0.98) 0.97 (0.96–0.98)
2 32,500 (76.3) 0.93 (0.92–0.93) 0.92 (0.92–0.93) 0.91 (0.89–0.93) 0.93 (0.92–0.94)
3 or more 7105 (72.4) 0.88 (0.87–0.89) 0.88 (0.87–0.89) 0.88 (0.84–0.92) 0.89 (0.87–0.91)
Mother’s age (years)
,25 21,999 (73.9) 0.91 (0.90–0.91) 0.91 (0.91–0.92) 0.91 (0.88–0.93) 0.93 (0.91–0.94)
25-,30 81,946 (79.6) 0.98 (0.97–0.98) 0.98 (0.98–0.98) 0.97 (0.95–0.99) 0.98 (0.98–0.99)
30-,35 97,386 (81.5) Ref. Ref. Ref. Ref.
35-40 48,715 (81.2) 1.00 (0.99–1.00) 1.00 (0.99–1.00) 1.00 (0.98–1.02) 1.00 (0.99–1.01)
$40 9655 (80.1) 0.98 (0.97–0.99) 0.98 (0.97–0.99) 0.97 (0.93–1.01) 0.98 (0.97–1.00)
Primary provider type
Pediatrician 171,512 (82.0) 1.16 (1.14–1.17) 1.13 (1.11–1.14) 1.23 (1.16–1.31) 1.14 (1.12–1.16)
Family physician 8554 (70.9) Ref. Ref. Ref. Ref.
Other providers 48,874 (77.4) 1.09 (1.08–1.11) 1.07 (1.06–1.08) 1.17 (1.10–1.24) 1.09 (1.07–1.11)
No consistent provider type 30,761 (77.1) 1.09 (1.07–1.10) 1.07 (1.06–1.08) 1.18 (1.11–1.25) 1.08 (1.06–1.10)
Network of provider type
In-network 234,753 (80.1) 1.01 (1.00–1.01) 1.00 (0.99–1.00) 1.00 (0.97–1.03) 0.97 (0.96–0.99)





3639 (81.0) 1.01 (1.00–1.03) 1.02 (1.00–1.03) 0.98 (0.91–1.04) 1.01 (0.99–1.03)
EPO or PPO 183,987 (79.8) Ref. Ref. Ref. Ref.
HMO 40,726 (80.9) 1.01 (1.01–1.02) 1.00 (1.00–1.01) 1.02 (1.00–1.04) 0.99 (0.98–1.00)
POS or POS with capitation 24,960 (80.2) 1.01 (1.00–1.01) 1.00 (1.00–1.01) 1.02 (1.00–1.05) 0.99 (0.98–1.01)
CDHP 6389 (81.2) 1.02 (1.01–1.03) 1.01 (1.00–1.02) 1.04 (0.99–1.08) 1.00 (0.99–1.02)
Region of residence
Northeast 29,415 (80.7) 1.01 (1.01–1.02) 0.99 (0.99–1.00) 1.05 (1.02–1.08) 0.97 (0.96–0.98)
Midwest 78,228 (80.8) 1.01 (1.01–1.02) 1.02 (1.02–1.03) 1.01 (1.00–1.03) 1.03 (1.02–1.03)
South 131,635 (79.8) Ref. Ref. Ref. Ref.
West 20,423 (78.5) 0.98 (0.98–0.99) 0.99 (0.98–0.99) 0.93 (0.90–0.97) 0.99 (0.98–1.00)
Type of residence
Metro with $1 M pop 160.617 (81.3) Ref. Ref. Ref. Ref.
Metro with 250,000 – 1 M pop 47,204 (81.1) 1.00 (0.99–1.00) 1.01 (1.00–1.01) 1.01 (0.99–1.03) 1.01 (1.00–1.02)
Metro with ,250,000 pop 24,533 (77.7) 0.96 (0.95–0.96) 0.98 (0.97–0.98) 0.96 (0.94–0.99) 0.98 (0.97–0.99)
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received among infants in our cohort (r = 0.76). Since our cohort
consisted of infants with private insurance who had at least one
outpatient record, failure to access the healthcare system cannot
fully explain why some infants did not receive recommended
vaccines, such as DTaP or rotavirus. Based on our results,
interventions aimed at increasing the coverage of any one
childhood vaccine may help increase the coverage and timeliness
of other recommended childhood vaccines, assuming that vaccine
availability is not an issue. This was shown to be the case for the
DTaP vaccine in Australia, where the third dose coverage of
DTaP vaccine in a pre-RV5 cohort was 80%, but increased by 5
to 12 percent once the RV5 vaccine was available and widely used
[14].
Overall, adherence to the 2009 ACIP guidelines for rotavirus
vaccine administration was high. Although we compared all years
of data (2006 to 2010) to the 2009 ACIP guidelines which are less
stringent than the 2006 ACIP guidelines, adherence remained
high even when we reanalyzed the 2006–2008 data using the 2006
ACIP guidelines (data not shown). Despite overall high levels of
compliance to the 2009 ACIP recommendations, ensuring that
infants complete the rotavirus vaccine series could be improved.
Other multi-dose vaccines face a similar challenge. Prior to
rotavirus vaccine availability, the vaccination histories of over
17,000 children in the 2005 NIS were reviewed, revealing that of
the 28% of children not compliant with ACIP recommendations,
two-thirds were categorized as such because they were missing
doses for multi-dose vaccinations [15]. However, since vaccination
coverage has been shown to increase as the number of physician
office visits increase, one remedy physicians could consider is
vaccinating infants at-risk for missing office visits with RV1 since it
requires only two doses to complete the series [16]. However, since
identifying infants at-risk for missing office visits can be difficult,
this recommendation may only be practical in theory. Further-
more, post-marketing data comparing partial series effectiveness of
RV5 to RV1 are limited [17].
In addition to the limitations already discussed, our analyses are
subject to the following additional limitations. First, many
variables potentially predictive of rotavirus vaccine uptake were
not available in our data. Further research is needed to examine
the effect of potentially relevant predictors, such as race, ethnicity,
family economic status, and physician reimbursement levels.
Second, we were unable to validate important estimated dates,
such as birth dates and rotavirus vaccination dates. While such
misclassifications could affect the results of our analysis that
assesses adherence to the 2009 ACIP recommendations, we do not
suspect that there was enough misclassification to affect our overall
conclusions and they are consistent with the results from another
recently published study [18]. Third, while we do not suspect that
the factors predicting RV5 uptake would differ from the factors
predicting RV1 uptake, our results mainly reflect patterns of RV5
use since 92% of the infants in our cohort exclusively received this
vaccine. Finally, the infants in our cohorts were not representative
of the US infant population; however, our study included nearly
600,000 infants with commercial insurance who may represent the
group of infants that most commonly utilizes the rotavirus
vaccines.
Conclusion
Our study revealed rapid initial uptake of the rotavirus vaccine
after licensure of RV5. However, even several years after
licensure, many children still did not receive the vaccine or
received an incomplete series. Quality improvement efforts should
focus on ensuring that (1) infants complete a rotavirus vaccine
series; (2) family physicians receive the adequate education and
support necessary to increase the rates of vaccination among
infants in their care; and (3) other recommended infant
vaccinations are administered.
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International Classification of Diseases, Ninth Revision; Jan,





















Urban with $20,000 pop,
adjacent to metro area
8095 (76.1) 0.94 (0.93–0.95) 0.96 (0.95–0.97) 0.87 (0.83–0.92) 0.99 (0.97–1.01)
Urban with $20,000 pop, 3869 (74.7) 0.92 (0.90–0.93) 0.94 (0.94–0.96) 0.91 (0.86–0.97) 0.95 (0.92–0.97)
not adjacent to metro area
Urban with 2500–19,999 pop,
adjacent to metro area
9000 (73.5) 0.90 (0.89–0.91) 0.93 (0.92–0.94) 0.91 (0.87–0.95) 0.94 (0.92–0.95)
Urban with 2500–19,999 pop, 3997 (70.0) 0.86 (0.85–0.88) 0.90 (0.88–0.91) 0.84 (0.78–0.90) 0.90 (0.87–0.92)
not adjacent to metro area
Rural or ,2500 population,
adjacent to metro area
1333 (77.3) 0.95 (0.93–0.97) 0.98 (0.95–1.0) 0.94 (0.84–1.04) 0.98 (0.94–1.03)
Rural or ,2500 population, 1053 (71.7) 0.88 (0.85–0.91) 0.92 (0.89–0.95) 1.03 (0.92–1.15) 0.92 (0.87–0.98)
not adjacent to metro area
Abbreviations: CDHP, Consumer Directed Health Plan; DTaP, diphtheria, tetanus, and acellular pertussis; EPO, Exclusive Provider Organization; HMO, Health Maintenance
Organization; Metro, metropolitan; Pop, population; POS, Point of Service; PPO, Preferred Provider Organization; RV1, monovalent rotavirus vaccine; RV5, pentavalent
rotavirus vaccine.
doi:10.1371/journal.pone.0073825.t003
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